<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277693</url>
  </required_header>
  <id_info>
    <org_study_id>1040338</org_study_id>
    <nct_id>NCT00277693</nct_id>
  </id_info>
  <brief_title>Cardiovascular Protective Effect of Spironolactone in Hemodialysis</brief_title>
  <official_title>Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Los Andes, Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Los Andes, Chile</source>
  <brief_summary>
    <textblock>
      The purpose of the present study is to determine if spironolactone is safe and effective in
      the treatment of cardiovascular complications in hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular complications are common in dialysis patients and comprise up to 50% of deaths
      in end-stage renal disease population. Hypertension and left ventricle hypertrophy occur in
      more than 70% of patients undergoing long-term hemodialysis therapy, and both contributes to
      mortality and morbidity.Recent clinical trials in chronic heart failure and post miocardial
      infarct heart failure patients have demonstrated a beneficial effect of a mineralocorticoid
      receptor blocker spironolactone, in adittion to standard therapy (RALES AND EPHESUS studies).
      The aim of the present study is to evaluate spironolactone treatment in hemodialysis
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Hemodialysis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        chronic hemodialysys (&gt; 3 months) anuria (diuresis &lt;200 mL/day) -

        Exclusion Criteria:

        Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or
        agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists
        Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Luis F Michea, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, University Los Andes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Vukusich, MD</last_name>
    <phone>56-2-7308021</phone>
    <email>avukusic@davila.cl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Davila</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Vukusich, MD</last_name>
      <phone>56-2-7308021</phone>
      <email>avukusic@davila.cl</email>
    </contact>
    <contact_backup>
      <last_name>Elisa T Marusic, PhD</last_name>
      <phone>56-2-4129341</phone>
      <email>emarusic@uandes.cl</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Vukusich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Michea L, Vukusich A, Gonz√°lez M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004 Oct;66(4):1647-53.</citation>
    <PMID>15458462</PMID>
  </reference>
  <verification_date>December 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2006</study_first_posted>
  <last_update_submitted>January 12, 2006</last_update_submitted>
  <last_update_submitted_qc>January 12, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2006</last_update_posted>
  <keyword>hemodialysis</keyword>
  <keyword>aldosterone</keyword>
  <keyword>heart failure</keyword>
  <keyword>spironolactone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

